Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-finding study of LXH254 alone or with PDR001 in MAPK pathway-altered advanced solid tumors
NL-OMON50657Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of naporafenib and spartalizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), ovarian cancer and 1 more (2 arms), sponsored by Novartis. Primary endpoints: Adverse events and Dose-limiting toxicities. Started Mar 2016; status: active, not recruiting.
02
Drugs
naporafenibspartalizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)ovarian cancermelanoma
Beyond the preview
Go deeper on NL-OMON50657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50657.